摘要
目的探究保济口服液联合奥美拉唑肠溶片治疗急性胃肠炎患者的效果及对胃肠激素和血清可溶性白细胞介素2受体(sIL-2R)、白细胞介素2(IL-2)与C反应蛋白(CRP)水平的影响。方法经随机数字表法将2023年1月至2024年5月北京中医医院顺义医院收治的106例急性胃肠炎患者分成对照组与观察组,各53例。对照组口服奥美拉唑肠溶片治疗,观察组在此基础上使用保济口服液治疗,比较两组治疗7 d后的临床疗效、临床症状消失时间、治疗前后的胃肠激素(胃泌素、胃动素、胃蛋白酶原Ⅰ和胃蛋白酶原Ⅱ)水平、血清炎症因子(sIL-2R、IL-2与CRP)水平及不良反应发生情况。结果治疗后,与对照组(79.25%,42/53)比较,观察组的总有效率(94.34%,50/53)较高(χ^(2)=5.267,P<0.05)。与对照组比较,观察组治疗后腹痛、腹泻、呕吐及发热症状消失时间均较早(P<0.05)。治疗后,观察组胃泌素、胃动素、胃蛋白酶原Ⅰ、胃蛋白酶原Ⅱ水平[分别为(133.59±22.57)ng·L^(-1)、(382.23±64.49)ng·L^(-1)、(128.38±21.42)ng·L^(-1)、(13.74±2.49)ng·L^(-1)]均较对照组[分别为(171.16±26.84)ng·L^(-1)、(326.72±51.65)ng·L^(-1)、(104.86±19.53)ng·L^(-1)、(17.95±3.27)ng·L^(-1)]有明显的改善(t=7.799、4.891、5.907、7.457,均P<0.05)。治疗后,两组血清sIL-2R与CRP水平均较治疗前降低,IL-2水平均较治疗前升高,且观察组sIL-2R、CRP、IL-2水平[分别为(304.52±40.96)kU·L^(-1)、(8.48±1.45)mg·L^(-1)、(71.29±12.73)ng·L^(-1)]均优于对照组[分别为(335.17±41.15)kU·L^(-1)、(12.19±3.29)mg·L^(-1)、(53.62±9.54)ng·L^(-1)],差异均有统计学意义(t=3.843、7.512、8.086,均P<0.05)。两组服药期间出现不良反应的总发生率对比差异无统计学意义(P>0.05)。结论用保济口服液配合奥美拉唑肠溶片治疗急性胃肠炎可快速缓解患者的临床症状,改善其胃肠功能,减轻机体的炎症反应,疗效突出,且不良反应少。
Objective To explore the efficacy of baoji oral liquid combined with omeprazole enteric-coated tablets in treatment of acute gastroenteritis and its influence on levels of gastrointestinal hormones,serum soluble interleukin-2 receptor(sIL-2R),interleukin-2(IL-2)and C-reactive protein(CRP).Methods According to random number table method,106 patients with acute gastroenteritis admitted to Shunyi Hospital,Beijing Traditional Chinese Medicine Hospital were divided into the control group and the observation group,with 53 in each group.The patients in the control group were treated with omeprazole enteric-coated tablets while those in the observation group were additionally treated with baoji oral liquid.After 7 d of treatment,clinical curative effect,disappearance time of clinical symptoms,gastrointestinal hormones(gastrin,motilin,pepsinogenⅠ,pepsinogenⅡ),serum inflammatory factors(sIL-2R,IL-2,CRP)and occurrence of adverse reactions were compared between the two groups.Results After treatment,the total effective rate of treatment was higher in the observation group than that in the control(94.34%(50/53)vs 79.25%(42/53))(χ^(2)=5.267,P<0.05).Compared with the control group,the observation group had earlier disappearance of abdominal pain,diarrhea,vomiting,and fever symptoms after treatment(P<0.05).The levels of gastrin,motilin,pepsinogen I and pepsinogenⅡwere(133.59±22.57)ng·L^(-1),(382.23±64.49)ng·L^(-1),(128.38±21.42)ng·L^(-1),(13.74±2.49)ng·L^(-1) in the observation group,which showed more significant improvement as compared with the control group((171.16±26.84)ng·L^(-1),(326.72±51.65)ng·L^(-1),(104.86±19.53)ng·L^(-1),(17.95±3.27)ng·L^(-1))(t=7.799,4.891,5.907,7.457,all P<0.05).The levels of serum sIL-2R and CRP were decreased in both groups,which were lower in the observation group((304.52±40.96)kU·L^(-1),(8.48±1.45)mg·L^(-1))than in the control group((335.17±41.15)kU·L^(-1),(12.19±3.29)mg·L^(-1))(t=3.843,7.512,both P<0.05).However,the level of serum IL-2 was increased and it was higher in the observation group((71.29±12.73)ng·L^(-1))than in the control group((53.62±9.54)ng·L^(-1))(t=8.086,P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups during medication(P>0.05).Conclusion Baoji oral liquid combined with omeprazole enteric-coated tablet can quickly relieve clinical symptoms,improve gastrointestinal function and alleviate inflammatory response in patients with acute gastroenteritis and it has significant curative effect and few adverse reactions.
作者
邹济源
武琛
王辉
陈林
焦云涛
左瑞菊
Zou Jiyuan;Wu Chen;Wang Hui;Chen Lin;Jiao Yuntao;Zuo Ruiju(Department of Spleen and Gastroenterology,Shunyi Hospital,Beijing Traditional Chinese Medicine Hospital,Beijing 101300,China;Department of Preventive Treatment,Shunyi Hospital,Beijing Traditional Chinese Medicine Hospital,Beijing 101300,China;Department of Traditional Chinese Medicine,Niulanshan Community Health Service Center,Shunyi District,Beijing 101301,China)
出处
《中国药物应用与监测》
2025年第5期899-903,共5页
Chinese Journal of Drug Application and Monitoring
基金
北京市属医院科研培育计划项目(P220201028)。
